The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
Open accessAbstract
Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers when compared with alendronate-treated subjects. This trial was designed to compare the efficacy and safety of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or weekly alendronate treatment and were considered to be suboptimally adherent to therapy. In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed. A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7 (6.9) years, mean (SD) BMD T-scores of -1.6 (0.9), -1.9 (0.7), and -2.2 (1.2) at the total hip, femoral neck, and lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab significantly increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar spine (3.4% vs 1.1%; p<0.0001 at all sites). Denosumab significantly decreased sCTX-1 compared with risedronate at month 1 (median change from baseline of -78% vs -17%; p<0.0001) and month 6 (-61% vs -23%; p<0.0001). Overall and serious adverse events were similar between groups. In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Denosumab is a fully human monoclonal antibody against RANKL, a cytokine that is an essential mediator for osteoclast formation, function, and survival [7].”
BackgroundOsteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Raisz, L. G. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042092 · Cited by 262
Cited by
Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 672
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Denosumab: A review in postmenopausal osteoporosis
Deeks, E. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0525-7 · Cited by 169
Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0179-z · Cited by 29
Metadata
- Authors
- Roux, C., Hofbauer, L. C., Ho, P. R., Wark, J. D., Zillikens, M. C., Fahrleitner-Pammer, A., Hawkins, F., Micaelo, M., Minisola, S., Papaioannou, N., Stone, M., Ferreira, I., Siddhanti, S., Wagman, R. B., & Brown, J. P.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 58
- Pages
- 48-54
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2135203315
- Cited by
- 158
- References
- 6
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. https://app.cochat.ai/papers/10.1016/j.bone.2013.10.006
- The paper
- Roux, C., Hofbauer, L. C., Ho, P. R., Wark, J. D., Zillikens, M. C., Fahrleitner-Pammer, A., Hawkins, F., Micaelo, M., Minisola, S., Papaioannou, N., Stone, M., Ferreira, I., Siddhanti, S., Wagman, R. B., & Brown, J. P. (2014). Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone. https://doi.org/10.1016/j.bone.2013.10.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.